title: Polymodal activation of the endocannabinoid system in the extended amygdala.
abstract: The reason why neurons synthesize more than one endocannabinoid (eCB) and how this is involved in the regulation of synaptic plasticity in a single neuron is not known. We found that 2-arachidonoylglycerol (2-AG) and anandamide mediate different forms of plasticity in the extended amygdala of rats. Dendritic L-type Ca(2+) channels and the subsequent release of 2-AG acting on presynaptic CB1 receptors triggered retrograde short-term depression. Long-term depression was mediated by postsynaptic mGluR5-dependent release of anandamide acting on postsynaptic TRPV1 receptors. In contrast, 2-AG/CB1R-mediated retrograde signaling mediated both forms of plasticity in the striatum. These data illustrate how the eCB system can function as a polymodal signal integrator to allow the diversification of synaptic plasticity in a single neuron.
authors: INSERM U862, Physiopathology of Synaptic Plasticity, Neurocentre Magendie, Bordeaux Cedex, France.
authors: Nagore
authors: N
authors: Puente
authors: Yihui
authors: Y
authors: Cui
authors: Olivier
authors: O
authors: Lassalle
authors: Mathieu
authors: M
authors: Lafourcade
authors: François
authors: F
authors: Georges
authors: Laurent
authors: L
authors: Venance
authors: Pedro
authors: P
authors: Grandes
authors: Olivier J
authors: OJ
authors: Manzoni
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D001703:Biophysics; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism / Q000648:ultrastructure; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism* / Q000494:pharmacology; D002867:Chromones / Q000494:pharmacology; D003512:Cyclohexanones / Q000494:pharmacology; D004558:Electric Stimulation; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005989:Glycerides / Q000378:metabolism; D066298:In Vitro Techniques; D036881:Long-Term Synaptic Depression / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D009553:Nimodipine / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism / Q000648:ultrastructure; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000378:metabolism / Q000648:ultrastructure; D012686:Septal Nuclei / Q000166:cytology* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013569:Synapses / Q000378:metabolism / Q000648:ultrastructure; D050916:TRPV Cation Channels / Q000378:metabolism / Q000648:ultrastructure; D013997:Time Factors
chemical_list: C117789:7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester; D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D063385:Cannabinoid Receptor Modulators; D002867:Chromones; C469526:Cnr2 protein, rat; D003512:Cyclohexanones; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D005989:Glycerides; C578937:Grm5 protein, rat; C419385:L-type calcium channel alpha(1C); D010880:Piperidines; D011720:Pyrazoles; D011725:Pyridines; D043885:Receptor, Cannabinoid, CB2; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; C103505:AM 251; D009553:Nimodipine; C121465:6-methyl-2-(phenylethynyl)pyridine; C036535:1,6-bis(cyclohexyloximinocarbonyl)hexane; C094503:glyceryl 2-arachidonate; D002118:Calcium